11/07/2025
中国投资人董寿伟博士致老挝人民革命党中央总书记、国家主席通伦·西苏里阁下的信
Letter from Chinese investor Dr. D**g Shouwei to His Excellency Thongloun Sisoulith, General Secretary of the Central Committee of the Lao People's Revolutionary Party and President of Laos
Your Excellency Mr. Thongloun Sisoulith,
President of the Lao People's Democratic Republic,
It is with immense excitement and profound reverence that I address this letter to you. To express my utmost respect and to articulate my thoughts with greater clarity, I have chosen to write in English, the international language I am most proficient in.
My name is D**g Shouwei. I was born in Shanghai, China, and am a researcher and scientist specializing in assisted reproductive medical technology. In my early years, I completed my Bachelor's, Master's, and Doctoral studies in Biophysics in Germany, participating in the research and development of specialized materials for the European Space Agency. In 2011, I served as the Deputy Editor-in-Chief for the Chinese national engineering machinery industry reference book, "China Road Construction and Maintenance Machinery Equipment Manual," and was the primary inventor of an inclinometer sensor. I also led the R&D for the fully automated manufacturing technology of micro-manipulation needles used in IVF (In Vitro Fertilization), filling a technological gap within China. These achievements have been recognized by the Chinese People's Political Consultative Conference (CPPCC), and relevant information can be found in my Baidu Baike (Baidu Encyclopedia) entry under "董寿伟" (D**g Shouwei).
Beyond my scientific work, I actively participate in public affairs, currently serving as a member of the Putuo District Committee of the CPPCC in Shanghai and as a member of the Healthcare and Sports Committee of the Shanghai Municipal Committee of the Revolutionary Committee of the Chinese Kuomintang (RCCK), among other roles.
In November 2022, I was invited to attend the China-Laos Mohan-Boten Economic Cooperation Zone Joint Investment Promotion Conference, hosted by the People's Government of Yunnan Province, China, during the Shanghai China International Import Expo. At the event, where Governor Wang Yubo of Yunnan Province delivered a speech, I was received by Mr. Li Chenyang, then Director-General of the Yunnan Provincial Department of Commerce. After reviewing the investment promotion policies for assisted reproductive medicine in Boten, Laos, issued by the Yunnan Department of Commerce, I initiated contact with the Boten Economic Special Zone Investment Promotion Bureau. In 2023, I formally signed a contract with the Boten Economic Zone Development Group Co., Ltd. (a wholly-owned subsidiary of Yunnan Hai Cheng Group), submitted my investment application to the Boten Special Economic Zone Administrative Committee Government, Luang Namtha Province, Laos, and successfully registered the Boten Pacclinic International Hospital. The hospital's core business scope encompasses assisted reproduction, stem cells, and clinical medical research.
From that point forward, my vision has been to dedicate my life's work, particularly my achievements in IVF micro-manipulation technology, to advancing medical technology in Laos. I am committed to establishing the Boten Pacclinic International Hospital project as a pinnacle of China-Laos cooperation under the Belt and Road Initiative. Furthermore, I aim to train and employ graduates from Lao medical universities in assisted reproductive technologies and collaborate closely with Lao health authorities to elevate the overall standard of healthcare in Laos. To this end, under my initiative, we established the Laos-China Medical Services Industry Association in Boten, Laos, in July 2024.
Human Assisted Reproductive Technology (ART), primarily referring to IVF, involves extracting s***m from the male partner and eggs from the female partner. These are then combined in a laboratory setting under specialized microscopes for fertilization. The resulting embryos are cultured in specific equipment. Utilizing advanced Preimplantation Genetic Testing (PGT), embryos with chromosomal abnormalities or genetic diseases are screened out, allowing the selection of healthy embryos for transfer back into the female's uterus for implantation and pregnancy. This is a high-end medical technology crucial for improving population quality, enabling healthy births, and safeguarding the health of women and children.
Significantly, this technology is not limited to humans; it also has vital applications in breeding high-quality dairy cattle, agricultural livestock, and endangered species. Boten Pacclinic International Hospital is willing to transfer this technology to Lao medical and livestock industry counterparts free of charge.
Our project is listed on the official Chinese Belt and Road portal and has received support from multiple Chinese government departments.
However, since October of last year, our aspirations in Boten, Laos, have suffered a severe setback.
**Boten Pacclinic International Hospital Application Process & Current Status:**
1. **Investment Promotion Phase (2022):** Attended Yunnan Provincial Gov't Investment Conference at Shanghai Import Expo; Received Gov't Promotion Handbook (**Explicitly Permitted** ART services).
2. **Case Studies Visited (2023):** Visited operational "Lao Genetics & Reproductive Specialist Hospital" in Boten (est. 2019) and Jinrui Boten reproductive center acquired by a HK listed company (in 2020） (**Both Operational**).
3. **Formal Contract Signing (2023):** Signed investment contract with Boten Economic Zone Development Group Co., Ltd. (**Contract Permitted** ART services).
4. **Pre-Investment Review (2023):** Submitted complete project documents (business plan, feasibility report, resumes, agreements) to Lao authorities (Luang Namtha Province Gov't, Boten SEZ Admin Committee, National Planning & Investment Dept.) per Lao Enterprise Law & Foreign Investment Promotion Law (**Review Approved**).
5. **Enterprise Establishment (2023):** Obtained Enterprise Registration Certificate & Tax Registration Certificate from MPI and Boten SEZ Admin Committee (**Certificates Explicitly Include** ART/IVF medical services, hospital operations, etc. - 6 items total).
6. **Trial Operation Permission (2024):** Granted permission by Boten SEZ Admin Committee & Investment Bureau to conduct trial operations for ART/IVF and stem cell medical services (**Explicit Permission Granted**).
7. **Problem Exposure (Oct 2024 - May 2025):** By May 2025, Boten IPB had attracted 13 ART/Stem Cell hospitals (Chinese, US, etc.). Lao Ministry of Public Security raided and sealed 5 of these hospitals in Oct 2024 and Apr 2025, confiscating equipment, detaining staff, etc(Pacclinic was NOT raided). This exposed serious irregularities in Boten's investment promotion (**Revealing de facto prohibition of ART services**).
8. **Operation Halted (2025):** Upon clarification: Despite prior investment approval and valid certificates, per Lao Medical Law, Guidelines for Establishing Private Hospitals, and Agreement on Surrogacy and Abortion Management, the Ministry of Health (MoH) prohibits private hospitals from providing ART/IVF services and refuses to issue the required medical practice license (**Operation Confirmed Impossible**).
To safeguard Laos's reputation as an international investment destination, I wrote to Mr. Bakhodir Burkhanov, the UN Resident Coordinator in Laos, in January of this year. He replied twice, confirming that the matter was referred to relevant central government departments in Laos. Concurrently, I have actively communicated with over a dozen Chinese entities, including the Chinese Embassy in Laos, the Ministry of Commerce, the Ministry of Foreign Affairs, the People's Governments of Yunnan Province and Shanghai Municipality, seeking their assistance in coordination.
On May 20, 2025, arranged by the Chinese Embassy in Laos, I met with Mr. Khamsay, Director-General of the Department of Healthcare and Rehabilitation, Lao Ministry of Health. While expressing sympathy for my situation, he clearly stated that although Boten Pacclinic Hospital had passed the investment review and legally obtained Enterprise and Tax Registration Certificates explicitly including ART/IVF medical services, he could not issue the medical practice license for ART/IVF to our private hospital under the current regulations of the MoH.
Your Excellency, as my background illustrates, I am not merely a businessman but a scientist in biomedical technology. I came to invest in Laos with the most sincere aspiration to foster collaboration and exchange in biomedical technology between China and Laos. I firmly believe Laos is undergoing a stage similar to the early days of China's Reform and Opening-up. Innovative endeavors beneficial to technological progress and national well-being often face initial skepticism. However, guided by your exceptional wisdom and foresight, any difficulty can be overcome. Under your leadership, the Lao government and people are achieving daily progress in technological and organizational innovation. You are the sun illuminating Laos's path of development.
I earnestly appeal for your attention and support regarding this matter. I am deeply committed to staying in this beautiful land of Laos and contributing to its development in the field of biomedical technology. May the friendship between Laos and China endure forever.
I look forward to your response. Thank you most sincerely for your valuable time.
Respectfully Yours,
Your Sincere International Collaborator,
D**g Shouwei
July 07, 2025
中文译文：
《中国投资人董寿伟博士致老挝人民革命党中央总书记、国家主席通伦·西苏里阁下的信》
敬爱的通伦·西苏里主席阁下：
怀着无比激动与崇敬的心情，我谨致信于您。为表达我对您的最高敬意，并更清晰地阐述我的想法，我选择使用我所掌握的最为熟练的国际语言——英文来撰写此信。
我是董寿伟，出生于中国上海，是一名专注于辅助生殖医疗科技的研究者与科学家。早年我在德国完成了生物物理学本科、硕士及博士学业，并参与了欧洲宇航局多项特殊材料的研发工作。2011年，我担任中国国家工程机械行业工具书《中国筑养路机械设备手册》副主编，同时是一种倾角传感器的第一发明人。我还主导了辅助生殖行业试管婴儿显微操作针全自动化制造技术的研发，填补了该技术在国内的空白。这些成就获得了中国政协组织的认可，相关信息可在百度百科“董寿伟”词条中查询。
除科研工作外，我也积极参与社会事务，现任上海市普陀区政协委员、民革上海市委会医卫体委员等职。
2022年11月，我受邀参加中国云南省人民政府在上海进博会期间主办的中国老挝磨憨-磨丁经济合作区联合招商会。会上，云南省王予波省长发表致辞，我有幸得到时任云南省商务厅厅长李晨阳先生的接待。在获悉云南省商务厅印发的关于老挝磨丁辅助生殖医疗招商政策后，我随即与老挝磨丁经济特区招商局对接。2023年，我正式与老挝磨丁经济专区开发集团有限公司签约，并向老挝琅南塔省磨丁经济特区政府提交了投资申请，成功注册了以辅助生殖、干细胞及临床医学研究为主营业务的磨丁太诊国际医院。
自此，我的愿景是运用毕生所学，特别是在试管婴儿显微操作技术研发领域的成果，服务于老挝医疗技术水平的提升。我致力于将磨丁太诊国际医院项目打造成为中老“一带一路”合作的典范，同时培养和吸纳老挝医科大学毕业生学习辅助生殖技术，并与老挝卫生部门通力合作，提升老挝整体医疗卫生水平。为此，在我的推动下，我们于2024年7月在老挝磨丁成立了老挝中华医疗服务业联合会。
人类辅助生殖技术（主要指试管婴儿技术），其核心流程是：将夫妇双方的精子和卵子分别取出，在实验室器皿中，由专业医疗人员在特殊显微镜下操作完成体外受精；受精卵在特定设备中培养成胚胎后，通过植入前遗传学诊断技术筛选染色体正常、无遗传疾病的优质胚胎，再将其移植回女方子宫内着床妊娠。这是一项旨在提高人口质量、实现优生优育、保障妇女儿童健康的高端医疗技术。
值得强调的是，此项技术不仅应用于人类生殖，亦可广泛应用于优质奶牛、农业牲畜及珍稀动物的繁殖。磨丁太诊国际医院愿无偿将此技术传授给老挝的医疗和畜牧业同行。
我们的项目已登陆中国官方的“一带一路”网，并得到了中国多个政府部门的支持。
然而，自去年10月起，我们在老挝磨丁的美好愿景遭遇了重大挫折。
**磨丁太诊国际医院申办流程与现状：**
1. **招商阶段 (2022年)：** 参加云南省政府于上海进博会主办的招商会；获得云南省政府招商政策手册（**明确允许**从事辅助生殖医疗服务）。
2. **考察案例 (2023年)：** 参观磨丁当地已开业的“老挝遗传生殖专科医院”（2019年开业）及某上市公司2020年公告收购的磨丁生殖中心（**均在运营**）。
3. **正式签约 (2023年)：** 与云南海诚集团全资子公司“老挝磨丁经济专区开发集团有限公司”签订投资合同（**合同许可**从事该业务）。
4. **投资前审查 (2023年)：** 依据老挝《企业法》、《外国投资促进法》，通过磨丁招商局向老挝琅南塔省政府、磨丁经济特区管委会及国家计划投资部等部门提交完整项目材料（**获得审查通过**）。
5. **企业设立 (2023年)：** 通过审查，成功获得老挝计划投资部及琅南塔经济特区管委会颁发的企业注册证及税务登记证（**证照包含**辅助生殖试管婴儿医疗服务、医院等6个项目）。
6. **试运营许可 (2024年)：** 获得磨丁经济特区管委会及招商局许可，开展辅助生殖及干细胞医疗业务试运营（**明确许可**）。
7. **问题暴露 (2024年10月-2025年5月)：** 截至2025年5月，磨丁招商局已引进13家中外辅助生殖/干细胞医院。老挝公安部于2024年10月和2025年4月两次突击查封其中5家医院，没收设备、拘押人员等（太诊国际医院未被查封）。此事暴露出磨丁存在严重的招商问题（**此时才知相关业务实际被禁止**）。
8. **运营受阻 (2025年)：** 经核实，虽然太诊医院项目已获投资批准且证照齐全，但依据老挝《医疗法》、《私立医院设立指导意见》及《代孕和堕胎管理协议》，卫生部禁止私立医院从事辅助生殖技术，拒绝批准相关医疗许可（**最终确认无法运营**）。
为维护老挝的国际投资环境声誉，我于今年1月致信联合国驻老挝协调员Bakhodir Burkhanov先生。他两次回信表示已将此事转呈老挝中央政府相关部门。同时，我也积极与中国驻老挝大使馆、中国商务部、外交部、云南省人民政府、上海市人民政府等十余个部门沟通，寻求协调解决。
2025年5月20日，在中国驻老挝大使馆安排下，我拜会了老挝卫生部医疗康复司司长Khamsay先生。他对我的遭遇表示同情，但明确指出：尽管太诊医院已通过投资准入审查并获得包含辅助生殖服务内容的合法企业注册证和税务登记证，但根据卫生部现行法规，他无法为作为私立医院的我们颁发辅助生殖技术医疗许可。
尊敬的主席阁下，从我的履历中您可以看到，我并非纯粹的商人，而是一名生物医疗科技工作者。我怀着推动中老生物医疗技术交流合作的最真诚愿望来到老挝投资。我深信，老挝正经历着类似中国改革开放初期的阶段，许多有益于技术进步和国民福祉的新生事物，其初始阶段难免受到质疑。但在您卓越的智慧和远见卓识领导下，任何困难都能被克服。在您的指引下，老挝政府和人民每天都在实现技术与组织的革新进步。您是照亮老挝发展道路的太阳。
我恳切地请求您对此事予以关注和支持。我渴望能继续留在老挝这片美丽的土地上，在生物医疗技术领域为老挝的发展贡献力量。愿老中友谊万古长青。
期待您的回复。衷心感谢您拨冗阅读此信。
此致
崇高的敬意！
您真诚的国际合作友人
董寿伟
2025年7月7日
